Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ENSYSCE BIOSCIENCES INC (ENSC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.36-2.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ENSC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Resolve Nasdaq listing compliance issues | Ensysce Biosciences aims to resolve Nasdaq listing issues to avoid delisting. | Improving | Nasdaq issues persist or worsen beyond 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage healthcare company, not an established earnings compounder. Its long-term thesis is intact, with the Cy Biopharma acquisition completed and PF614-MPAR advancing, but losses and volatile management keep the risk high.
The valuation evidence is mixed: ENSC is described as cheap versus peers, while the peer comparison also shows a 15% premium. The expectations gap is negative, but model confidence is low, so what the market assumes is uncertain; the priced-in assessment is tagged justified, with no fragility flags.
Near-term results have been neutral overall, including a reported earnings beat, while recent performance sits in the top half of its industry. The acquisition adds CY200 and funding that is expected to support cash runway into late 2027, with potential extension to 2028, but operating losses and cash use remain substantial. Clinical activity is progressing, though the next report carries elevated miss risk for a small company in a high-miss-rate industry.
Over the next one to three years, the thesis hinges on clinical progress, especially PF614-MPAR, and whether funding is enough to manage ongoing losses. Healthcare sector momentum could remain supportive if VRTX, REGN, and MRNA continue to report strong results, while weaker jobs data or disappointing sector results could reduce that support.
ENSC has delivered initial progress on its acquisition and development priorities, but it remains a high-risk, loss-making business with limited evidence on how its programs will develop over time. The multi-year view is intact but depends on clinical execution, cash management, and sector conditions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company targets reducing operating losses near negative $3.56 million and improving revenue above $0.96 million next quarter. |
| Improving |
| Operating losses worsen beyond negative $3.56 million next quarter |
Operating income: $-2.576M FY2026-Q2; GAAP. Published target: Operating losses <= negative $3.56 million next quarter. The stored target says 2026-Q3; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-2,576,389 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue near $0.96 million | The company targets reducing operating losses near negative $3.56 million and improving revenue above $0.96 million next quarter. | Intact | Revenue falls below $0.96 million next quarter | Revenue: $1.164M FY2026-Q2; GAAP. Published target: Revenue >= $0.96 million next quarter. The stored target says 2026-Q3; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 20261,164,315 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.11 → $-0.06 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-07-25 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-07-26 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-07-27 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-07-28 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-07-29 | $-0.11 | Unavailable | 1 / 0 |
| 2026-07-30 | $-0.11 | Unavailable | 1 / 0 |
| 2026-07-31 | $-0.11 | Unavailable | 1 / 0 |
| 2026-08-01 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-02 | $-0.11 | Unavailable | 1 / 0 |
| 2026-08-03 | $-0.11 | Unavailable | 1 / 0 |
| 2026-08-04 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-05 | $-0.11 | Unavailable | 1 / 0 |
| 2026-08-06 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-07 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-08 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-09 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-10 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-11 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-12 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-13 | $-0.05 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-15 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-16 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-17 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-18 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-19 | $-0.11 | $2,500,000 | 1 / 1 |
| 2026-08-20 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-21 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-22 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-23 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-24 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-25 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-26 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-27 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-28 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-29 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-30 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-08-31 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-01 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-02 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-03 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-04 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-05 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-06 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-07 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-08 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-09 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-10 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-11 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-12 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-13 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-14 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-15 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-16 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-17 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-18 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-19 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-20 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-21 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-22 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-23 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-24 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-25 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-26 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-27 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-28 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-29 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-09-30 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-01 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-02 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-03 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-04 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-05 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-06 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-07 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-08 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-09 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-10 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-11 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-12 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-13 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-14 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-15 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-16 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-17 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-18 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-19 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-20 | $-0.06 | $2,500,000 | 1 / 1 |
| 2026-10-21 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-22 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-23 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-24 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-25 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-26 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-27 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-28 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-29 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-30 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-10-31 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-11-01 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-11-02 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-11-03 | $-0.06 | $2,750,000 | 1 / 1 |
| 2026-11-04 | $-0.06 | $2,750,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.